小柿西
Lv5
1040 积分
2023-04-30 加入
-
Evolocumab como tratamiento de la dislipemia secundaria a lorlatinibEvolocumab as treatment in lorlatinib-related hyperlipidemia
1个月前
已完结
-
Lorlatinib – Induced pulmonary arterial hypertension
1个月前
已完结
-
Metabolism, Excretion, and Pharmacokinetics of Lorlatinib (PF‐06463922) and Evaluation of the Impact of Radiolabel Position and Other Factors on Comparability of Data Across 2 ADME Studies
1个月前
已完结
-
The CLIP1–LTK fusion is an oncogenic driver in non‐small‐cell lung cancer
1个月前
已完结
-
Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations
1个月前
已完结
-
FSP1 oxidizes NADPH to suppress ferroptosis
2个月前
已完结
-
Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegeneration with an LXR agonist
2个月前
已完结
-
The hypothalamic steroidogenic pathway mediates susceptibility to inflammation-evoked depression in female mice
3个月前
已完结
-
Lorlatinib for the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer
6个月前
已完结
-
Insight into the effect of a heavy metal mixture on neurological damage in rats through combined serum metabolomic and brain proteomic analyses
7个月前
已完结